Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 21, 2022

Sequencing of Ipilimumab+Nivolumab and Encorafenib+Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
J. Clin. Oncol 2022 Sep 01;[EPub Ahead of Print], PA Ascierto, M Mandalà, PF Ferrucci, M Guidoboni, P Rutkowski, V Ferraresi, A Arance, M Guida, E Maiello, H Gogas, E Richtig, MT Fierro, C Lebbè, H Helgadottir, P Queirolo, F Spagnolo, M Tucci, M Del Vecchio, M Gonzales Cao, AM Minisini, S De Placido, MF Sanmamed, D Mallardo, M Curvietto, I Melero, G Palmieri, AM Grimaldi, D Giannarelli, R Dummer, V Chiarion Sileni

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading